Can Kanvas Biosciences turn microbiome replacement into a maternal health intervention?
Maternal EED lacks scalable therapies. Kanvas Biosciences now faces the harder test: proving microbiome replacement can work where need is greatest.
AptarGroup enters Phase II POSITS study as delivery partner for ENA Respiratory’s INNA-051 nasal spray
Aptar’s UDS Powder system enters ENA Respiratory’s POSITS Phase II trial. Analyse what INNA-051 must prove in 2026 and why the device choice matters. Read more.
Can philanthropic capital succeed where pharma failed in Gram-negative antibiotic discovery?
Will Gr-ADI fix the broken antibiotic pipeline? Explore how Gates, Novo, and Wellcome aim to reboot AMR innovation with $60M in global grants.